Editorial: Heterogeneity and plasticity of prostate cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F23%3A00574523" target="_blank" >RIV/68081707:_____/23:00574523 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1228126/full" target="_blank" >https://www.frontiersin.org/journals/molecular-biosciences/articles/10.3389/fmolb.2023.1228126/full</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Editorial: Heterogeneity and plasticity of prostate cancer

Popis výsledku v původním jazyce

Prostate cancer represents a highly heterogeneous and one of the most clinically common malignancies in men. Despite the improvement in the management of localized prostate cancer, therapy options for the advanced stages of the disease remain limited. Resistance to endocrine and chemotherapy treatments in prostate cancer is a subject of ongoing discussion and investigation. Limited understanding of the extent of cellular plasticity, clonality and intratumoral heterogeneity in the context of therapy resistance remains one of the main bottlenecks of current prostate cancer research. There is an increased number of novel drugs available. However, the mechanisms that are relevant to therapy resistance are incompletely understood and additional studies are needed. The ultimate goal may be to establish evidence-based drug sequences on the basis of understanding the action of transcription factors, oncogenic and tumor-suppressive miRNA in prostate cancer. Another challenge for experimental therapy is the existence of stem cells which may be targeted by some drugs originally implemented in non-malignant diseases.

Název v anglickém jazyce

Editorial: Heterogeneity and plasticity of prostate cancer

Popis výsledku anglicky

Prostate cancer represents a highly heterogeneous and one of the most clinically common malignancies in men. Despite the improvement in the management of localized prostate cancer, therapy options for the advanced stages of the disease remain limited. Resistance to endocrine and chemotherapy treatments in prostate cancer is a subject of ongoing discussion and investigation. Limited understanding of the extent of cellular plasticity, clonality and intratumoral heterogeneity in the context of therapy resistance remains one of the main bottlenecks of current prostate cancer research. There is an increased number of novel drugs available. However, the mechanisms that are relevant to therapy resistance are incompletely understood and additional studies are needed. The ultimate goal may be to establish evidence-based drug sequences on the basis of understanding the action of transcription factors, oncogenic and tumor-suppressive miRNA in prostate cancer. Another challenge for experimental therapy is the existence of stem cells which may be targeted by some drugs originally implemented in non-malignant diseases.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10608 - Biochemistry and molecular biology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů